GLG News by Hologic's LORAD Selenia Full Field Digital Mammography System Users

A single payer, national system does work, but may not necessarily be in the best interest of all parties.   Yes this type of system is 'free' to the users, but is funded through higher taxes than paid in the US.

Varian and Elekta's new arc treatments improve workflow, efficiency, and give radiation oncologists a better alternative to tomotherapy.    

This is a big hit for Pfizer - a costly product they licensed due to lack of good pipeline products.   Unfortunatley, I don't think they anticipated the issues surrounding the complexity of inhaled insulin, properly marketed the product, or did enough research on the patient side (ie compliane,...

Cardiovascular disease in breast cancer is a real risk.   As our population is aging, and breast cancer is one of the most comon cancers, it is up to us to minimize risks of treatment related morbidity.

While the data between avastin and lucentis is pending, it's interesting to see Genetch trying to defending profits at the expense of patients.   Genetech has impeded this trial, so that they could defend sales of Lucentis. Before lucentis was approved, avastin was used for macular degeneration...

Glioblastoma multiforme are one of the worst tumors one can have - period.   Even with aggressive surgery, chemotherapy and radiation, most of these patients succumb to their disease within 1 year.   Initial results of Avastin + Irinotecan look promising as a second line regimen.  ...

Fentora is a great, but potentially dangerous product. With it's significant narcotic effect, it should only be prescirbed to appropriate patients by those with experience. The recent deaths were likely due to poor patient selection and lack of experience by the providers.  

The STAR trial was a follow-up to the P1 trial, evaluating whether raloxifene (Evista) could be used as a preventive agent. The results were supportive of this agent in this role, and hence the FDA has approved it. There is a black box warning on stroke risk, though the results did not show a significantly...

Given the recent data on erythropoietin, this study further demonstrates the significant potential adverse events seen. Expect sales to continue to decrease, as erythropoietin drugs in the future will be used in renal failure and oncology patients to keep hematocrits in a reasonable range.

Previous data on Iressa has shown no survival benefit.   This phase III trial comparing Iressa to Taxotere in locally advanced phase III NSCLC seems to show equivalence.   And, clearly the Iressa was more favorable than taxotere. If the data is true, this will reignite the question...